SB/21 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/588,602
Filing Date	August 7, 2006
First Named Inventor	Quinn Tang
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned

Total Number of Pages in This Submission		Not Yet Assigned	INTM/019 US

ENCLOSURES *(Check all that apply)*

☐ Fee Transmittal Form (in duplicate)

   ☐ Fee Attached

☒ Preliminary Amendment and Response to Notification of Defective Response (in duplicate)

☐ Assertion of Small Entity Status under 37 C.F.R. § 1.27(c)(1)

☐ Supplemental Application Data Sheet

☐ Declaration (executed)

☐ Certified Copy of Priority Document(s)

☐ Reply to Missing Parts/ Incomplete Application

☒ Sequence Listing (Computer readable diskette)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

   ☐ Landscape Table on CD

☐ After Allowance Communication to TC

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please Identify below):
1. Statement under 37 CFR §§ 1.825(a) and (b);
2. Paper copy of Sequence Listing (54 pages);
3. Copy of Notification of Defective Response, including marked-up Raw Sequence Listing; and
4. Postcard.

Remarks

The Director is hereby authorized to charge any fee due, or to credit any overpayment, in connection with this submission to Deposit Account No. 06-1075, Order No. 104825-0019. A duplicate copy of this Transmittal is enclosed herewith.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Ropes & Gray LLP
Signature	*Alla P___*
Printed name	Alla Brukman
Date	July 10, 2008	Reg. No.	61,254

CERTIFICATE OF EXPRESS MAIL TRANSMISSION – Express Mail No.: EM014769592US

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

Signature	*Sarah Schlie*		
Typed or printed name	SARAH SCHLIE	Date	July 10, 2008

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkflow.com

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/588,602
Filing Date	August 7, 2006
First Named Inventor	Quinn Tang
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned

Total Number of Pages in This Submission		Not Yet Assigned	INTM/019 US

ENCLOSURES *(Check all that apply)*

- [ ] Fee Transmittal Form (in duplicate)
  - [ ] Fee Attached
- [x] Preliminary Amendment and Response to Notification of Defective Response (in duplicate)
- [ ] Assertion of Small Entity Status under 37 C.F.R. § 1.27(c)(1)
- [ ] Supplemental Application Data Sheet
- [ ] Declaration (executed)
- [ ] Certified Copy of Priority Document(s)
- [ ] Reply to Missing Parts/ Incomplete Application

- [x] Sequence Listing (Computer readable diskette)
- [ ] Licensing-related Papers
- [ ] Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Request for Refund
- [ ] CD, Number of CD(s) _____
  - [ ] Landscape Table on CD

- [ ] After Allowance Communication to TC
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- [ ] Proprietary Information
- [ ] Status Letter
- [x] Other Enclosure(s) (please Identify below):
  1. Statement under 37 CFR §§ 1.825(a) and (b);
  2. Paper copy of Sequence Listing (54 pages);
  3. Copy of Notification of Defective Response, including marked-up Raw Sequence Listing; and
  4. Postcard.

Remarks

The Director is hereby authorized to charge any fee due, or to credit any overpayment, in connection with this submission to Deposit Account No. 06-1075, Order No. 104825-0019. A duplicate copy of this Transmittal is enclosed herewith.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Ropes & Gray LLP
Signature	*(signature)*
Printed name	Alla Brukman
Date	July 10, 2008	Reg. No.	61,254

CERTIFICATE OF EXPRESS MAIL TRANSMISSION – Express Mail No.: EM014769592US

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

Signature	*(signature)*		
Typed or printed name	**SARAH SCHLIE**	Date	July 10, 2008

UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/588,602	Quinn Tang	INTM/019 US

1473
ROPES & GRAY LLP
PATENT DOCKETING 39/361
1211 AVENUE OF THE AMERICAS
NEW YORK, NY 10036-8704

INTERNATIONAL APPLICATION NO.	
PCT/US05/03857	
I.A. FILING DATE	PRIORITY DATE
02/07/2005	02/05/2004

CONFIRMATION NO. 7130
371 FORMALITIES LETTER

OC000000030387715

Date Mailed: 06/10/2008

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- Indication of Small Entity Status
- Priority Document
- Copy of the International Application filed on 08/07/2006
- Copy of the International Search Report filed on 08/07/2006 .
- Copy of IPE Report filed on 08/07/2006
- Copy of Annexes to the IPER filed on 08/07/2006
- Preliminary Amendments filed on 08/07/2006
- Biochemical Sequence Diskette filed on 06/13/2007
- Oath or Declaration filed on 06/13/2007
- Biochemical Sequence Listing filed on 06/13/2007
- Small Entity Statement filed on 06/13/2007
- U.S. Basic National Fees filed on 08/07/2006
- Priority Documents filed on 08/07/2006
- Paper nucleotide sequence listings filed on 06/13/2007

Applicant's response filed 06/13/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 04/13/2007 have not been completed.

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Refer to attachment or PAIR document dated 02-21-2008.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

FORM PCT/DO/EO/916 (371 Formalities Notice)

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
   • **For Rules Interpretation, call (571) 272-0951**
   • **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
   • **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

KAREN R MCLEAN

Telephone: (703) 308-9140 EXT 214

```
============================================================
```
Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2007; month=11; day=27; hr=14; min=13; sec=36; ms=956;]
```
============================================================
```

```
************************************************************
```
Reviewer Comments:

<210> 1

<211> 21

<212> DNA

<213> Mus musculus

<400> 1

aagccgtcct gtgtgccgct g

Please insert a cumulative nucleotide total at the right margin. This type of error appears globally. FYI: per Sequence Rules, the maximum number of characters per line (includes white spaces) is 72.
```
************************************************************
```

Validated By CRFValidator v 1.0.3

Application No: 10588602   Version No: 1.0

Input Set:

Output Set:

Started: 2007-11-02 19:37:59.191
Finished: 2007-11-02 19:38:05.924
Elapsed: 0 hr(s) 0 min(s) 6 sec(s) 733 ms
Total Warnings: 22
Total Errors: 373
No. of SeqIDs Defined: 374
Actual SeqID Count: 374

Error code	Error Description
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(1)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(2)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(3)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(4)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(5)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 10 SEQID(7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 15 SEQID(8)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(9)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

Input Set:

Output Set:

Started:	2007-11-02 19:37:59.191
Finished:	2007-11-02 19:38:05.924
Elapsed:	0 hr(s) 0 min(s) 6 sec(s) 733 ms
Total Warnings:	22
Total Errors:	373
No. of SeqIDs Defined:	374
Actual SeqID Count:	374

Error code		Error Description
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 47 SEQID(13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 47 SEQID(14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 47 SEQID(15)
W	213	Artificial or Unknown found in <213> in SEQ ID (16)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(16)
W	213	Artificial or Unknown found in <213> in SEQ ID (17)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(17)
W	213	Artificial or Unknown found in <213> in SEQ ID (18)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(18)
W	213	Artificial or Unknown found in <213> in SEQ ID (19)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(19)
W	213	Artificial or Unknown found in <213> in SEQ ID (20)
E	254	The total number of bases conflicts with running total Input: 0, Calculated : 20 SEQID(20) This error has occured more than 20 times, will not be displayed
W	213	Artificial or Unknown found in <213> in SEQ ID (21)

Input Set:

Output Set:

Started:	2007-11-02 19:37:59.191
Finished:	2007-11-02 19:38:05.924
Elapsed:	0 hr(s) 0 min(s) 6 sec(s) 733 ms
Total Warnings:	22
Total Errors:	373
No. of SeqIDs Defined:	374
Actual SeqID Count:	374

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)
W 213	Artificial or Unknown found in <213> in SEQ ID (24)
W 213	Artificial or Unknown found in <213> in SEQ ID (25)
W 213	Artificial or Unknown found in <213> in SEQ ID (26)
W 213	Artificial or Unknown found in <213> in SEQ ID (27)
W 213	Artificial or Unknown found in <213> in SEQ ID (28)

This error has occured more than 20 times, will not be displayed

SEQUENCE LISTING

<110> TANG, QUINN
       LU, PATRICK
       XIE, FRANK
       WOODLE, MARTIN

<120> RNAI THERAPEUTICS FOR TREATMENT OF EYE
       NEOVASCULARIZATION DISEASES

<130> INTM/019 US

<140> 10588602
<141> 2007-11-02

<150> PCT/US05/003857
<151> 2005-02-07

<150> 60/541,775
<151> 2004-02-05

<160> 374

<170> PatentIn Ver. 3.3

<210> 1
<211> 21
<212> DNA
<213> Mus musculus

<400> 1
aagccgtcct gtgtgccgct g

<210> 2
<211> 21
<212> DNA
<213> Mus musculus

<400> 2
aacgatgaag ccctggagtg c

<210> 3
<211> 21
<212> DNA
<213> Mus musculus

<400> 3
aagttaaaag tgcctgaact g

<210> 4
<211> 21
<212> DNA
<213> Mus musculus

```
<400> 4
aagcaggcca gactctcttt c


<210> 5
<211> 21
<212> DNA
<213> Mus musculus

<400> 5
aagctcagca cacagaaaga c

<210> 6
<211> 21
<212> DNA
<213> Mus musculus

<400> 6
aatgcggcgg tggtgacagt a


<210> 7
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 7
tcaacgttga


<210> 8
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 8
gctagacgtt agcgt


<210> 9
<211> 21
<212> DNA
<213> Escherichia coli

<400> 9
aacagttgcg cagcctgaat g
```

```
<210> 10
<211> 21
<212> DNA
<213> Escherichia coli

<400> 10
aacttaatcg ccttgcagca c


<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<400> 11
aagctatgaa acgatatggg c


<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<400> 12
aaccgctgga gagcaactgc a


<210> 13
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<400> 13
gaacatcgat gacaagctta ggtatcgata caagctgcct cgccttg


<210> 14
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer
```

<400> 14

gaacatcgat gacaagctta ggtatcgata tagattgaag attccgc

<210> 15
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<400> 15

gaacatcgat gacaagctta ggtatcgata ggtcactgac agaggcg

<210> 16
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<400> 16

gaacatcgat gacaagctta ggtatcgata

<210> 17
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<400> 17

gatgtctacc agcgaagcta ctgccgtccg

<210> 18
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<400> 18

gtcagctgct gggacaccgc ggtcttgcct

<210> 19

<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 19
ggcgctgcta gctgtcgctc tgtggttctg

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 20
cctggtcacc agggctgctt

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 21
ccagccttct ccatggtggt

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 22
gcgggctgcc tcgcagtc

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
      primer

<400> 23
tcaccgcctt ggcttgtcac

<210> 24
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 24
catcctgcac caccaactgc ttag

<210> 25
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 25
gcctgcttca ccaccttctt gatg

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 26
gccagcacat agagagaatg agc

<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 27
caaggctcac agtgattttc tgg

<210> 28
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 28
Ala Cys Arg Gly Asp Met Phe Gly Cys Ala
  1   5   10

<210> 29
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 29
aagctgaccc tgaagttcat c

<210> 30
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 30
aagcagcacg acttcttcaa g

<210> 31
<211> 21
<212> DNA
<213> Homo sapiens

<400> 31
aagtggtccc aggctgcacc c

<210> 32
<211> 21
<212> DNA
<213> Homo sapiens

<400> 32
aagatccgca gacgtgtaaa t

<210> 33
<211> 21
<212> DNA
<213> Homo sapiens

<400> 33
aaacacagac tcgcgttgca a

<210> 34
<211> 21
<212> DNA
<213> Homo sapiens

<400> 34
aacacagact cgcgttgcaa g

<210> 35
<211> 21
<212> DNA
<213> Homo sapiens

<400> 35
aaggcgaggc agcttgagtt a

<210> 36
<211> 21
<212> DNA
<213> Homo sapiens

<400> 36
aaacgaacgt acttgcagat g

<210> 37
<211> 21
<212> DNA
<213> Homo sapiens

<400> 37
aacgaacgta cttgcagatg t

<210> 38
<211> 21
<212> DNA
<213> Homo sapiens

<400> 38
aacgtacttg cagatgtgac a

<210> 39

<211> 21
<212> DNA
<213> Homo sapiens

<400> 39
aatcgagacc ctggtggaca t

<210> 40
<211> 21
<212> DNA
<213> Homo sapiens

<400> 40
aaggccagca cataggagag a

<210> 41
<211> 21
<212> DNA
<213> Homo sapiens

<400> 41
aaggaggagg gcagaatcat c

<210> 42
<211> 21
<212> DNA
<213> Homo sapiens

<400> 42
aatgcagacc aaagaaagat a

<210> 43
<211> 21
<212> DNA
<213> Homo sapiens

<400> 43
aatgtgaatg cagaccaaag a

<210> 44
<211> 21
<212> DNA
<213> Homo sapiens

<400> 44
aacatcacca tgcagattat g

<210> 45
<211> 21
<212> DNA
<213> Homo sapiens

<400> 45
aagcatttgt ttgtacaaga t

<210> 46
<211> 21
<212> DNA
<213> Homo sapiens

<400> 46
aagtggtgaa gttcatggat g

<210> 47
<211> 21
<212> DNA
<213> Homo sapiens

<400> 47
aagatagagc aagacaagaa a

<210> 48
<211> 21
<212> DNA
<213> Homo sapiens

<400> 48
aatccctgtg ggccttgctc a

<210> 49
<211> 21
<212> DNA
<213> Homo sapiens

<400> 49
aaatgtgaat gcagaccaaa g

<210> 50
<211> 21
<212> DNA
<213> Homo sapiens

<400> 50
aatgacgagg gcctggagtg t

<210> 51
<211> 21
<212> DNA
<213> Homo sapiens

<400> 51
aaagtggtgt catggataga t

<210> 52
<211> 21
<212> DNA
<213> Homo sapiens

<400> 52
aagtggtgtc atggatagat g

<210> 53
<211> 21
<212> DNA
<213> Homo sapiens

<400> 53
aaacagctgg tgcccagctg c

<210> 54
<211> 21
<212> DNA
<213> Homo sapiens

<400> 54
aagtccggat gcagatcctc a

<210> 55
<211> 21
<212> DNA
<213> Homo sapiens

<400> 55
aagaacacag ccagtgtgaa t

<210> 56
<211> 21
<212> DNA
<213> Homo sapiens

<400> 56
aacacagcca gtgtgaatgc a

<210> 57
<211> 21
<212> DNA
<213> Homo sapiens

<400> 57
aaaggacagt gctgtgaagc c

<210> 58

```
<211> 21
<212> DNA
<213> Homo sapiens

<400> 58
aaggacagtg ctgtgaagcc a


<210> 59
<211> 21
<212> DNA
<213> Homo sapiens

<400> 59
aagccagaca gggctgccac t


<210> 60
<211> 21
<212> DNA
<213> Homo sapiens

<400> 60
aacccagaca cctgcaggtg c


<210> 61
<211> 21
<212> DNA
<213> Homo sapiens

<400> 61
aaggagagga cctgaaactg t


<210> 62
<211> 21
<212> DNA
<213> Homo sapiens

<400> 62
aagcaaggag ggcctctgat g


<210> 63
<211> 21
<212> DNA
<213> Homo sapiens

<400> 63
aaggagggcc tctgatggtg a


<210> 64
<211> 21
<212> DNA
<213> Homo sapiens
```

<400> 64
aactacctca agagcaaacg t

<210> 65
<211> 21
<212> DNA
<213> Homo sapiens

<400> 65
aagtggccag aggcatggag t

<210> 66
<211> 21
<212> DNA
<213> Homo sapiens

<400> 66
aaagtgcatt catcgggacc t

<210> 67
<211> 21
<212> DNA
<213> Homo sapiens

<400> 67
aagtgcattc atcgggacct g

<210> 68
<211> 21
<212> DNA
<213> Homo sapiens

<400> 68
agcacgctgt ttattgaaag a

<210> 69
<211> 21
<212> DNA
<213> Homo sapiens

<400> 69
aagggcttca tcatatcaaa t

<210> 70
<211> 21
<212> DNA
<213> Homo sapiens

<400> 70
aaaggctgag cataactaaa t

<210> 71
<211> 21
<212> DNA
<213> Homo sapiens

<400> 71
aaggtcttct tctgaaataa a

<210> 72
<211> 21
<212> DNA
<213> Homo sapiens

<400> 72
aatgccatac tgacaggaaa t

<210> 73
<211> 21
<212> DNA
<213> Homo sapiens

<400> 73
aagaggatgc agggaattat a

<210> 74
<211> 21
<212> DNA
<213> Homo sapiens

<400> 74
aaggcgacga attgaccaaa g

<210> 75
<211> 21
<212> DNA
<213> Homo sapiens

<400> 75
aagatcctga actgagttta a

<210> 76
<211> 21
<212> DNA
<213> Homo sapiens

<400> 76
aaggctgagc ataactaaat c

<210> 77

<211> 21
<212> DNA
<213> Homo sapiens

<400> 77
aaggccaaga tttgcagaac t

<210> 78
<211> 21
<212> DNA
<213> Homo sapiens

<400> 78
aacacctcag tgcatatata t

<210> 79
<211> 21
<212> DNA
<213> Homo sapiens

<400> 79
aaagggcttc atcatatcaa a

<210> 80
<211> 21
<212> DNA
<213> Homo sapiens

<400> 80
aatcctccag aagaaagaaa t

<210> 81
<211> 21
<212> DNA
<213> Homo sapiens

<400> 81
aacagaattt cctgggacag c

<210> 82
<211> 21
<212> DNA
<213> Homo sapiens

<400> 82
aactgaagac aggctacttg t

<210> 83
<211> 21
<212> DNA
<213> Homo sapiens

<400> 83
aaggacttcc tgaccttgga g

<210> 84
<211> 21
<212> DNA
<213> Homo sapiens

<400> 84
aagtggctaa gggcatggag t

<210> 85
<211> 21
<212> DNA
<213> Homo sapiens

<400> 85
aagggcatgg agttcttggc a

<210> 86
<211> 21
<212> DNA
<213> Homo sapiens

<400> 86
aaatgtacca gaccatgctg g

<210> 87
<211> 21
<212> DNA
<213> Homo sapiens

<400> 87
aattccatta tgacaacaca g

<210> 88
<211> 21
<212> DNA
<213> Homo sapiens

<400> 88
aacagtaagc gaaagagccg g

<210> 89
<211> 21
<212> DNA
<213> Homo sapiens

<400> 89
atgacaacac agcaggaatc a

```
<210> 90
<211> 21
<212> DNA
<213> Homo sapiens

<400> 90
aagctcagca cacagaaaga c


<210> 91
<211> 21
<212> DNA
<213> Homo sapiens

<400> 91
aatgcggcgg tggtgacagt a


<210> 92
<211> 21
<212> DNA
<213> Homo sapiens

<400> 92
aatgccacca tgttctctaa t


<210> 93
<211> 21
<212> DNA
<213> Homo sapiens

<400> 93
aagctcctga agatctgtat a


<210> 94
<211> 21
<212> DNA
<213> Homo sapiens

<400> 94
aagcagatgc ctttggaatt g


<210> 95
<211> 21
<212> DNA
<213> Homo sapiens

<400> 95
aagcggctac cagtccggat a


<210> 96
```

<211> 21
<212> DNA
<213> Homo sapiens

<400> 96
aagtccctca gtgatgtaga a

<210> 97
<211> 21
<212> DNA
<213> Homo sapiens

<400> 97
aagtgcttct accgggaaac t

<210> 98
<211> 21
<212> DNA
<213> Homo sapiens

<400> 98
aatccctgtg gatctgaaac g

<210> 99
<211> 21
<212> DNA
<213> Homo sapiens

<400> 99
aaggctaata caactcttca a

<210> 100
<211> 21
<212> DNA
<213> Homo sapiens

<400> 100
aatcccattt caaaggagaa g

<210> 101
<211> 21
<212> DNA
<213> Homo sapiens

<400> 101
aagtggatag agagagctaa t

<210> 102
<211> 21
<212> DNA
<213> Homo sapiens

```
<400> 102
aaggctgctg gattccagta t


<210> 103
<211> 21
<212> DNA
<213> Homo sapiens

<400> 103
aagcagtctg tgattgaaat g


<210> 104
<211> 21
<212> DNA
<213> Homo sapiens

<400> 104
aagccctcat cactggttgt g


<210> 105
<211> 21
<212> DNA
<213> Homo sapiens

<400> 105
aaaggacatg gttagaatta a


<210> 106
<211> 21
<212> DNA
<213> Homo sapiens

<400> 106
aaggccttgg ccgtctggtt a


<210> 107
<211> 21
<212> DNA
<213> Homo sapiens

<400> 107
aagggtgtca ggtatttctt a


<210> 108
<211> 21
<212> DNA
<213> Homo sapiens

<400> 108
aatggagcga agctttcata t
```

```
<210> 109
<211> 21
<212> DNA
<213> Homo sapiens

<400> 109
aagtactgtg aagatgttaa t


<210> 110
<211> 21
<212> DNA
<213> Homo sapiens

<400> 110
aaggacatgg ttagaattaa c


<210> 111
<211> 21
<212> DNA
<213> Homo sapiens

<400> 111
aaggtactct cgcaggaaat g


<210> 112
<211> 21
<212> DNA
<213> Homo sapiens

<400> 112
aaacggaggc tgtgaacata t


<210> 113
<211> 21
<212> DNA
<213> Homo sapiens
```